X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (19) 19
immunotherapy (18) 18
oncology (18) 18
anti-pd-1 (14) 14
humans (14) 14
anti‐pd‐1 (13) 13
cancer (13) 13
nivolumab (11) 11
immune checkpoint (9) 9
apoptosis (8) 8
care and treatment (8) 8
clinical trials (8) 8
female (8) 8
pembrolizumab (8) 8
programmed cell death 1 receptor - antagonists & inhibitors (8) 8
analysis (7) 7
anti-pd-1 antibody (7) 7
antibodies (7) 7
ipilimumab (7) 7
metastasis (7) 7
anti‐pd‐1 antibody (6) 6
lung cancer (6) 6
lymphocytes t (6) 6
male (6) 6
middle aged (6) 6
patients (6) 6
tumors (6) 6
aged (5) 5
anti-ctla-4 (5) 5
chemotherapy (5) 5
dermatology (5) 5
melanoma (5) 5
metastases (5) 5
radiation (5) 5
radiation therapy (5) 5
safety (5) 5
t cells (5) 5
therapy (5) 5
viral antibodies (5) 5
adult (4) 4
animals (4) 4
anti-pd-l1 (4) 4
antibodies, monoclonal - adverse effects (4) 4
antineoplastic agents - adverse effects (4) 4
anti‐ctla‐4 (4) 4
anti‐pd‐l1 (4) 4
cancer therapies (4) 4
cell death (4) 4
cell line, tumor (4) 4
combination (4) 4
ctla-4 protein (4) 4
immune system (4) 4
lymphocytes (4) 4
medical research (4) 4
monoclonal antibodies (4) 4
original (4) 4
abridged index medicus (3) 3
antibodies, monoclonal - therapeutic use (3) 3
antineoplastic agents - therapeutic use (3) 3
antitumor activity (3) 3
article (3) 3
blockade (3) 3
brain neoplasms - immunology (3) 3
case reports (3) 3
cell biology (3) 3
ctla-4 antigen - antagonists & inhibitors (3) 3
cytotoxicity (3) 3
docetaxel (3) 3
drug eruptions - etiology (3) 3
drug eruptions - pathology (3) 3
glioblastoma (3) 3
glioblastoma multiforme (3) 3
immune response (3) 3
inhibitors (3) 3
liver neoplasms - drug therapy (3) 3
lung cancer, non-small cell (3) 3
medical prognosis (3) 3
melanoma - immunology (3) 3
melanoma - pathology (3) 3
metastatic melanoma (3) 3
mice (3) 3
neoplasm staging (3) 3
open-label (3) 3
pd-1 (3) 3
programmed cell death 1 receptor - immunology (3) 3
programmed cell death 1 receptor - metabolism (3) 3
radiotherapy (3) 3
research (3) 3
survival rate (3) 3
xenograft model antitumor assays (3) 3
aged, 80 and over (2) 2
anti-pd 1 (2) 2
anti-pd-l1 antibody (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
antineoplastic agents - pharmacology (2) 2
antineoplastic agents, immunological - administration & dosage (2) 2
antineoplastic agents, immunological - adverse effects (2) 2
antineoplastic agents, immunological - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
b7-h1 antigen - antagonists & inhibitors (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 12/2019, Volume 125, Issue S24, pp. 4616 - 4622
Despite advances in surgery and chemotherapy and the integration of antivascular endothelial growth factor therapy as well as poly(adenosine... 
immunotherapy combinations | antiprogrammed cell death protein 1 (anti‐PD‐1) | ovarian cancer | immunotherapy | antiprogrammed death‐ligand 1 (anti‐PD‐L1) | checkpoint inhibitor
Journal Article
Cancer, ISSN 0008-543X, 10/2016, Volume 122, Issue 19, pp. 3051 - 3058
Journal Article
Cancer, ISSN 0008-543X, 11/2016, Volume 122, Issue 21, pp. 3354 - 3362
Journal Article
Head & Neck, ISSN 1043-3074, 03/2019, Volume 41, Issue 3, pp. E42 - E47
Background The application of anti‐programmed death‐1 (PD‐1) therapies for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) has found... 
treatment beyond progression | anti‐PD‐1 | recurrent or metastatic HNSCC | nivolumab | anti-PD-1 | SURGERY | IMMUNOTHERAPY | OTORHINOLARYNGOLOGY | CANCER | CHEMOTHERAPY | Development and progression | Squamous cell carcinoma | Metastasis | Chemotherapy | Platinum | Medical prognosis | Immunotherapy | Case reports | Head and neck cancer | Radiation therapy | Synergism | Metastases | Apoptosis
Journal Article
Journal Article
Journal Article
International Journal of Cancer, ISSN 0020-7136, 06/2018, Volume 142, Issue 11, pp. 2344 - 2354
Journal Article
International Journal of Cancer, ISSN 0020-7136, 01/2016, Volume 138, Issue 1, pp. 187 - 194
Glioblastoma is the most aggressive primary central nervous system malignancy with a poor prognosis in patients. Despite the need for better treatments against... 
anti‐PD‐1 | glioblastoma | IL‐15 superagonist | ALT‐803 | IL-15 superagonist | ALT-803 | anti-PD-1 | GLIOMAS | CANCER | RADIATION | CD8(+) T-CELLS | TEMOZOLOMIDE | ONCOLOGY | IMMUNOTHERAPY | IMMUNOSUPPRESSION | INTERLEUKIN-15 | BLOCKADE | EXPRESSION | T-Lymphocyte Subsets - immunology | Humans | Radiosurgery | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Central Nervous System Neoplasms - immunology | T-Lymphocyte Subsets - drug effects | Immunotherapy | Female | Glioblastoma - metabolism | Lymphocytes, Tumor-Infiltrating - metabolism | Antineoplastic Agents - pharmacology | Disease Models, Animal | Central Nervous System Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Programmed Cell Death 1 Receptor - metabolism | Central Nervous System Neoplasms - therapy | Glioblastoma - therapy | Xenograft Model Antitumor Assays | Central Nervous System Neoplasms - pathology | Animals | Interleukin-15 - agonists | Glioblastoma - immunology | T-Lymphocyte Subsets - metabolism | Glioblastoma - pathology | Cell Line, Tumor | Immunologic Memory | Mice | Proteins - pharmacology | Glioblastoma - mortality | Central Nervous System Neoplasms - mortality | Lymphocytes, Tumor-Infiltrating - immunology | Killer cells | Immune response | Interleukins | Analysis | Health aspects | Glioblastoma multiforme | Cytokines | Medical prognosis | Immune system
Journal Article
Clinical & Translational Immunology, ISSN 2050-0068, 2019, Volume 8, Issue 11, p. n/a
Objectives Investigation of variable response rates to cancer immunotherapies has exposed the immunosuppressive tumor microenvironment (TME) as a limiting... 
tissue‐specific microenvironment | anti‐PD‐1 | trimAb | anti‐CTLA‐4 | tumor microenvironment
Journal Article
Pigment Cell & Melanoma Research, ISSN 1755-1471, 09/2019, Volume 32, Issue 5, pp. 687 - 696
Journal Article